Eli Lilly has completed its acquisition of Prevail Therapeutics, establishing a new modality for drug discovery and development at Lilly.
It will extend its research efforts through the creation of a gene therapy program that will be anchored by Prevail’s portfolio of clinical-stage and preclinical neuroscience assets.
“We are pleased to complete the acquisition of Prevail and establish a gene therapy program at Lilly that has the potential to deliver transformative treatments for patients with neurodegenerative diseases such as Parkinson’s, Gaucher and dementia,” said Mark Mintun, Vice President of pain and neurodegeneration research at Lilly.
The acquisition is worth a total of $1.040 billion.
